GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Retained Earnings

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Retained Earnings : $-35.80 Mil (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. CERo Therapeutics Holdings's retained earnings for the quarter that ended in Dec. 2022 was $-35.80 Mil.

CERo Therapeutics Holdings's quarterly retained earnings increased from . 20 ($0.00 Mil) to Dec. 2021 ($-23.97 Mil) but then declined from Dec. 2021 ($-23.97 Mil) to Dec. 2022 ($-35.80 Mil).

CERo Therapeutics Holdings's annual retained earnings increased from . 20 ($0.00 Mil) to Dec. 2021 ($-23.97 Mil) but then declined from Dec. 2021 ($-23.97 Mil) to Dec. 2022 ($-35.80 Mil).


CERo Therapeutics Holdings Retained Earnings Historical Data

The historical data trend for CERo Therapeutics Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Retained Earnings Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Retained Earnings
-23.97 -35.80

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Retained Earnings -23.97 -35.80

CERo Therapeutics Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


CERo Therapeutics Holdings  (NAS:CERO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines